nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—ABCB1—peripheral nervous system neoplasm	0.192	1	CbGaD
Lansoprazole—CYP4A11—Tretinoin—peripheral nervous system neoplasm	0.151	0.255	CbGbCtD
Lansoprazole—CYP2C18—Tretinoin—peripheral nervous system neoplasm	0.0662	0.112	CbGbCtD
Lansoprazole—CYP4A11—Cisplatin—peripheral nervous system neoplasm	0.0647	0.109	CbGbCtD
Lansoprazole—ABCG2—Topotecan—peripheral nervous system neoplasm	0.0321	0.0541	CbGbCtD
Lansoprazole—CYP1A1—Tretinoin—peripheral nervous system neoplasm	0.0275	0.0464	CbGbCtD
Lansoprazole—CYP1A1—Dacarbazine—peripheral nervous system neoplasm	0.0237	0.0399	CbGbCtD
Lansoprazole—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.0222	0.0375	CbGbCtD
Lansoprazole—CYP1B1—Doxorubicin—peripheral nervous system neoplasm	0.018	0.0304	CbGbCtD
Lansoprazole—CYP2C8—Tretinoin—peripheral nervous system neoplasm	0.0159	0.0268	CbGbCtD
Lansoprazole—ABCG2—Vincristine—peripheral nervous system neoplasm	0.0137	0.0231	CbGbCtD
Lansoprazole—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0132	0.0223	CbGbCtD
Lansoprazole—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.0128	0.0215	CbGbCtD
Lansoprazole—ABCG2—Etoposide—peripheral nervous system neoplasm	0.0125	0.0212	CbGbCtD
Lansoprazole—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0116	0.0195	CbGbCtD
Lansoprazole—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0116	0.0195	CbGbCtD
Lansoprazole—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0111	0.0187	CbGbCtD
Lansoprazole—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0106	0.0178	CbGbCtD
Lansoprazole—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.00855	0.0144	CbGbCtD
Lansoprazole—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.00801	0.0135	CbGbCtD
Lansoprazole—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.00693	0.0117	CbGbCtD
Lansoprazole—CYP2C8—Etoposide—peripheral nervous system neoplasm	0.00668	0.0113	CbGbCtD
Lansoprazole—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.00644	0.0109	CbGbCtD
Lansoprazole—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.00517	0.00873	CbGbCtD
Lansoprazole—ABCB1—Vincristine—peripheral nervous system neoplasm	0.00493	0.00833	CbGbCtD
Lansoprazole—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.00474	0.00801	CbGbCtD
Lansoprazole—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0046	0.00777	CbGbCtD
Lansoprazole—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00452	0.00763	CbGbCtD
Lansoprazole—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00308	0.00521	CbGbCtD
Lansoprazole—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00296	0.00499	CbGbCtD
Lansoprazole—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00291	0.00491	CbGbCtD
Lansoprazole—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00271	0.00457	CbGbCtD
Lansoprazole—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00185	0.00312	CbGbCtD
Lansoprazole—Pantoprazole—ABCB1—peripheral nervous system neoplasm	0.000414	0.551	CrCbGaD
Lansoprazole—Omeprazole—ABCB1—peripheral nervous system neoplasm	0.000337	0.449	CrCbGaD
Lansoprazole—MAPT—BDNF signaling pathway—BDNF—peripheral nervous system neoplasm	0.000201	0.00691	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—NTRK1—peripheral nervous system neoplasm	0.000194	0.00667	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.000192	0.00661	CbGpPWpGaD
Lansoprazole—MAPT—LPA receptor mediated events—CASP3—peripheral nervous system neoplasm	0.000192	0.00661	CbGpPWpGaD
Lansoprazole—CYP3A4—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.000191	0.00659	CbGpPWpGaD
Lansoprazole—CYP4A11—PPAR Alpha Pathway—MYC—peripheral nervous system neoplasm	0.000178	0.00614	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—BDNF—peripheral nervous system neoplasm	0.000178	0.00611	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	0.000175	0.00602	CbGpPWpGaD
Lansoprazole—MAPT—LKB1 signaling events—TP53—peripheral nervous system neoplasm	0.000169	0.00582	CbGpPWpGaD
Lansoprazole—MAPT—IL-2 Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000165	0.00568	CbGpPWpGaD
Lansoprazole—MAPT—Alzheimers Disease—CASP3—peripheral nervous system neoplasm	0.000162	0.00558	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	0.00016	0.00552	CbGpPWpGaD
Lansoprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—ABCB1—peripheral nervous system neoplasm	0.000159	0.00547	CbGpPWpGaD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	0.000159	0.00546	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	0.000158	0.00542	CbGpPWpGaD
Lansoprazole—MAPT—Notch Signaling Pathway—MYC—peripheral nervous system neoplasm	0.000156	0.00536	CbGpPWpGaD
Lansoprazole—MAPT—IL-5 Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000151	0.00521	CbGpPWpGaD
Lansoprazole—MAPT—IL-2 Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000146	0.00501	CbGpPWpGaD
Lansoprazole—MAPT—Copper homeostasis—TP53—peripheral nervous system neoplasm	0.000145	0.005	CbGpPWpGaD
Lansoprazole—CYP4A11—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000143	0.00493	CbGpPWpGaD
Lansoprazole—MAPT—BDNF signaling pathway—PTPN11—peripheral nervous system neoplasm	0.00014	0.00481	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000137	0.0047	CbGpPWpGaD
Lansoprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—HSD17B12—peripheral nervous system neoplasm	0.000136	0.00469	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	0.000136	0.00468	CbGpPWpGaD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000129	0.00445	CbGpPWpGaD
Lansoprazole—MAPT—Kit receptor signaling pathway—HRAS—peripheral nervous system neoplasm	0.000126	0.00432	CbGpPWpGaD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—ABCB1—peripheral nervous system neoplasm	0.000125	0.00431	CbGpPWpGaD
Lansoprazole—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000124	0.00426	CbGpPWpGaD
Lansoprazole—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.000123	0.00425	CbGpPWpGaD
Lansoprazole—MAPT—Copper homeostasis—AKT1—peripheral nervous system neoplasm	0.000123	0.00422	CbGpPWpGaD
Lansoprazole—MAPT—LPA receptor mediated events—HRAS—peripheral nervous system neoplasm	0.000118	0.00405	CbGpPWpGaD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000115	0.00397	CbGpPWpGaD
Lansoprazole—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000113	0.00388	CbGpPWpGaD
Lansoprazole—MAPT—Kit receptor signaling pathway—AKT1—peripheral nervous system neoplasm	0.000111	0.00382	CbGpPWpGaD
Lansoprazole—CYP4A11—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.00011	0.00378	CbGpPWpGaD
Lansoprazole—MAPT—Notch Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000108	0.00372	CbGpPWpGaD
Lansoprazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000107	0.0037	CbGpPWpGaD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000104	0.00358	CbGpPWpGaD
Lansoprazole—MAPT—Alzheimers Disease—TP53—peripheral nervous system neoplasm	0.000104	0.00358	CbGpPWpGaD
Lansoprazole—MAPT—LPA receptor mediated events—AKT1—peripheral nervous system neoplasm	0.000104	0.00358	CbGpPWpGaD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000102	0.00351	CbGpPWpGaD
Lansoprazole—MAPT—BDNF signaling pathway—CASP3—peripheral nervous system neoplasm	0.0001	0.00345	CbGpPWpGaD
Lansoprazole—MAPT—Apoptosis—CASP3—peripheral nervous system neoplasm	9.46e-05	0.00326	CbGpPWpGaD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	9.27e-05	0.00319	CbGpPWpGaD
Lansoprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	9.18e-05	0.00316	CbGpPWpGaD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	9.1e-05	0.00313	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PPIP5K2—peripheral nervous system neoplasm	9.01e-05	0.0031	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—CASP3—peripheral nervous system neoplasm	8.87e-05	0.00305	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	8.82e-05	0.00304	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	8.81e-05	0.00303	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	8.57e-05	0.00295	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	8.01e-05	0.00276	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PPIP5K2—peripheral nervous system neoplasm	7.88e-05	0.00271	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	7.82e-05	0.00269	CbGpPWpGaD
Lansoprazole—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	7.44e-05	0.00256	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—NRAS—peripheral nervous system neoplasm	7.44e-05	0.00256	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	7.28e-05	0.00251	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	7.19e-05	0.00247	CbGpPWpGaD
Lansoprazole—ABCG2—Fluoropyrimidine Activity—TP53—peripheral nervous system neoplasm	7.1e-05	0.00244	CbGpPWpGaD
Lansoprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	7.09e-05	0.00244	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—MYC—peripheral nervous system neoplasm	6.93e-05	0.00238	CbGpPWpGaD
Lansoprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—peripheral nervous system neoplasm	6.3e-05	0.00217	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	6.25e-05	0.00215	CbGpPWpGaD
Lansoprazole—MAPT—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	6.15e-05	0.00212	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—HSD17B12—peripheral nervous system neoplasm	6.09e-05	0.00209	CbGpPWpGaD
Lansoprazole—MAPT—Apoptosis—TP53—peripheral nervous system neoplasm	6.07e-05	0.00209	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	5.81e-05	0.002	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	5.72e-05	0.00197	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—TP53—peripheral nervous system neoplasm	5.69e-05	0.00196	CbGpPWpGaD
Lansoprazole—MAPT—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	5.43e-05	0.00187	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	5.42e-05	0.00187	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.32e-05	0.00183	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	5.28e-05	0.00182	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	5.13e-05	0.00177	CbGpPWpGaD
Lansoprazole—MAPT—Apoptosis—AKT1—peripheral nervous system neoplasm	5.12e-05	0.00176	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	5.08e-05	0.00175	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	5.06e-05	0.00174	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	4.97e-05	0.00171	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	4.82e-05	0.00166	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—AKT1—peripheral nervous system neoplasm	4.8e-05	0.00165	CbGpPWpGaD
Lansoprazole—Renal failure—Epirubicin—peripheral nervous system neoplasm	4.71e-05	0.000254	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	4.71e-05	0.000253	CcSEcCtD
Lansoprazole—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	4.71e-05	0.000253	CcSEcCtD
Lansoprazole—Fatigue—Etoposide—peripheral nervous system neoplasm	4.7e-05	0.000253	CcSEcCtD
Lansoprazole—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	4.7e-05	0.000253	CcSEcCtD
Lansoprazole—Stomatitis—Epirubicin—peripheral nervous system neoplasm	4.67e-05	0.000252	CcSEcCtD
Lansoprazole—Jaundice—Epirubicin—peripheral nervous system neoplasm	4.67e-05	0.000252	CcSEcCtD
Lansoprazole—Pain—Etoposide—peripheral nervous system neoplasm	4.67e-05	0.000251	CcSEcCtD
Lansoprazole—Constipation—Etoposide—peripheral nervous system neoplasm	4.67e-05	0.000251	CcSEcCtD
Lansoprazole—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	4.66e-05	0.000251	CcSEcCtD
Lansoprazole—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	4.66e-05	0.000251	CcSEcCtD
Lansoprazole—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	4.65e-05	0.00025	CcSEcCtD
Lansoprazole—Dysuria—Doxorubicin—peripheral nervous system neoplasm	4.65e-05	0.00025	CcSEcCtD
Lansoprazole—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	4.62e-05	0.000249	CcSEcCtD
Lansoprazole—Dizziness—Alitretinoin—peripheral nervous system neoplasm	4.62e-05	0.000249	CcSEcCtD
Lansoprazole—Diarrhoea—Vincristine—peripheral nervous system neoplasm	4.61e-05	0.000248	CcSEcCtD
Lansoprazole—Sweating—Epirubicin—peripheral nervous system neoplasm	4.6e-05	0.000247	CcSEcCtD
Lansoprazole—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	4.6e-05	0.000247	CcSEcCtD
Lansoprazole—Haematuria—Epirubicin—peripheral nervous system neoplasm	4.57e-05	0.000246	CcSEcCtD
Lansoprazole—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	4.54e-05	0.000244	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	4.53e-05	0.000244	CcSEcCtD
Lansoprazole—Weight increased—Doxorubicin—peripheral nervous system neoplasm	4.53e-05	0.000244	CcSEcCtD
Lansoprazole—Epistaxis—Epirubicin—peripheral nervous system neoplasm	4.52e-05	0.000243	CcSEcCtD
Lansoprazole—Sinusitis—Epirubicin—peripheral nervous system neoplasm	4.5e-05	0.000242	CcSEcCtD
Lansoprazole—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	4.5e-05	0.000242	CcSEcCtD
Lansoprazole—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	4.49e-05	0.000242	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	4.49e-05	0.00154	CbGpPWpGaD
Lansoprazole—Nausea—Dactinomycin—peripheral nervous system neoplasm	4.48e-05	0.000241	CcSEcCtD
Lansoprazole—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	4.47e-05	0.000241	CcSEcCtD
Lansoprazole—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	4.46e-05	0.00024	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	4.46e-05	0.00024	CcSEcCtD
Lansoprazole—Dizziness—Vincristine—peripheral nervous system neoplasm	4.45e-05	0.00024	CcSEcCtD
Lansoprazole—Vomiting—Alitretinoin—peripheral nervous system neoplasm	4.44e-05	0.000239	CcSEcCtD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	4.44e-05	0.00153	CbGpPWpGaD
Lansoprazole—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	4.44e-05	0.000239	CcSEcCtD
Lansoprazole—Infestation—Doxorubicin—peripheral nervous system neoplasm	4.44e-05	0.000239	CcSEcCtD
Lansoprazole—Rash—Alitretinoin—peripheral nervous system neoplasm	4.41e-05	0.000237	CcSEcCtD
Lansoprazole—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	4.4e-05	0.000237	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism—GNS—peripheral nervous system neoplasm	4.4e-05	0.00151	CbGpPWpGaD
Lansoprazole—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	4.4e-05	0.000237	CcSEcCtD
Lansoprazole—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	4.39e-05	0.000236	CcSEcCtD
Lansoprazole—Bradycardia—Epirubicin—peripheral nervous system neoplasm	4.38e-05	0.000236	CcSEcCtD
Lansoprazole—Headache—Alitretinoin—peripheral nervous system neoplasm	4.38e-05	0.000236	CcSEcCtD
Lansoprazole—Renal failure—Doxorubicin—peripheral nervous system neoplasm	4.36e-05	0.000235	CcSEcCtD
Lansoprazole—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	4.35e-05	0.000234	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	4.33e-05	0.00149	CbGpPWpGaD
Lansoprazole—Urticaria—Etoposide—peripheral nervous system neoplasm	4.33e-05	0.000233	CcSEcCtD
Lansoprazole—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	4.32e-05	0.000233	CcSEcCtD
Lansoprazole—Jaundice—Doxorubicin—peripheral nervous system neoplasm	4.32e-05	0.000233	CcSEcCtD
Lansoprazole—Rhinitis—Epirubicin—peripheral nervous system neoplasm	4.32e-05	0.000232	CcSEcCtD
Lansoprazole—Abdominal pain—Etoposide—peripheral nervous system neoplasm	4.31e-05	0.000232	CcSEcCtD
Lansoprazole—Body temperature increased—Etoposide—peripheral nervous system neoplasm	4.31e-05	0.000232	CcSEcCtD
Lansoprazole—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	4.31e-05	0.000232	CcSEcCtD
Lansoprazole—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	4.31e-05	0.000232	CcSEcCtD
Lansoprazole—Hepatitis—Epirubicin—peripheral nervous system neoplasm	4.3e-05	0.000232	CcSEcCtD
Lansoprazole—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	4.28e-05	0.00023	CcSEcCtD
Lansoprazole—Vomiting—Vincristine—peripheral nervous system neoplasm	4.28e-05	0.00023	CcSEcCtD
Lansoprazole—Asthenia—Cisplatin—peripheral nervous system neoplasm	4.27e-05	0.00023	CcSEcCtD
Lansoprazole—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	4.27e-05	0.00023	CcSEcCtD
Lansoprazole—Sweating—Doxorubicin—peripheral nervous system neoplasm	4.25e-05	0.000229	CcSEcCtD
Lansoprazole—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	4.25e-05	0.000229	CcSEcCtD
Lansoprazole—Rash—Vincristine—peripheral nervous system neoplasm	4.25e-05	0.000229	CcSEcCtD
Lansoprazole—Dermatitis—Vincristine—peripheral nervous system neoplasm	4.24e-05	0.000228	CcSEcCtD
Lansoprazole—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	4.24e-05	0.000228	CcSEcCtD
Lansoprazole—Haematuria—Doxorubicin—peripheral nervous system neoplasm	4.23e-05	0.000228	CcSEcCtD
Lansoprazole—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	4.23e-05	0.000228	CcSEcCtD
Lansoprazole—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	4.22e-05	0.000227	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism—NME1—peripheral nervous system neoplasm	4.22e-05	0.00145	CbGpPWpGaD
Lansoprazole—Headache—Vincristine—peripheral nervous system neoplasm	4.22e-05	0.000227	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	4.2e-05	0.000226	CcSEcCtD
Lansoprazole—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	4.18e-05	0.000225	CcSEcCtD
Lansoprazole—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	4.16e-05	0.000224	CcSEcCtD
Lansoprazole—Nausea—Alitretinoin—peripheral nervous system neoplasm	4.15e-05	0.000223	CcSEcCtD
Lansoprazole—Visual impairment—Epirubicin—peripheral nervous system neoplasm	4.15e-05	0.000223	CcSEcCtD
Lansoprazole—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	4.14e-05	0.000223	CcSEcCtD
Lansoprazole—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	4.07e-05	0.000219	CcSEcCtD
Lansoprazole—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	4.07e-05	0.000219	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism—COX2—peripheral nervous system neoplasm	4.06e-05	0.0014	CbGpPWpGaD
Lansoprazole—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	4.05e-05	0.000218	CcSEcCtD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	4.05e-05	0.00139	CbGpPWpGaD
Lansoprazole—Eye disorder—Epirubicin—peripheral nervous system neoplasm	4.02e-05	0.000216	CcSEcCtD
Lansoprazole—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	4.02e-05	0.000216	CcSEcCtD
Lansoprazole—Tinnitus—Epirubicin—peripheral nervous system neoplasm	4.01e-05	0.000216	CcSEcCtD
Lansoprazole—Nausea—Vincristine—peripheral nervous system neoplasm	4e-05	0.000215	CcSEcCtD
Lansoprazole—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	3.99e-05	0.000215	CcSEcCtD
Lansoprazole—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	3.99e-05	0.000215	CcSEcCtD
Lansoprazole—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	3.98e-05	0.000214	CcSEcCtD
Lansoprazole—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	3.96e-05	0.000213	CcSEcCtD
Lansoprazole—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	3.95e-05	0.000213	CcSEcCtD
Lansoprazole—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	3.93e-05	0.000212	CcSEcCtD
Lansoprazole—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	3.92e-05	0.000211	CcSEcCtD
Lansoprazole—CYP1B1—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.92e-05	0.00135	CbGpPWpGaD
Lansoprazole—Asthenia—Etoposide—peripheral nervous system neoplasm	3.91e-05	0.000211	CcSEcCtD
Lansoprazole—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	3.91e-05	0.000211	CcSEcCtD
Lansoprazole—Angiopathy—Epirubicin—peripheral nervous system neoplasm	3.91e-05	0.00021	CcSEcCtD
Lansoprazole—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	3.9e-05	0.00021	CcSEcCtD
Lansoprazole—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	3.89e-05	0.000209	CcSEcCtD
Lansoprazole—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	3.88e-05	0.000209	CcSEcCtD
Lansoprazole—Chills—Epirubicin—peripheral nervous system neoplasm	3.86e-05	0.000208	CcSEcCtD
Lansoprazole—Pruritus—Etoposide—peripheral nervous system neoplasm	3.86e-05	0.000208	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—GNS—peripheral nervous system neoplasm	3.85e-05	0.00132	CbGpPWpGaD
Lansoprazole—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	3.85e-05	0.000207	CcSEcCtD
Lansoprazole—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	3.84e-05	0.000207	CcSEcCtD
Lansoprazole—Alopecia—Epirubicin—peripheral nervous system neoplasm	3.8e-05	0.000205	CcSEcCtD
Lansoprazole—Vomiting—Cisplatin—peripheral nervous system neoplasm	3.79e-05	0.000204	CcSEcCtD
Lansoprazole—Mental disorder—Epirubicin—peripheral nervous system neoplasm	3.77e-05	0.000203	CcSEcCtD
Lansoprazole—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	3.77e-05	0.000203	CcSEcCtD
Lansoprazole—Rash—Cisplatin—peripheral nervous system neoplasm	3.75e-05	0.000202	CcSEcCtD
Lansoprazole—Dermatitis—Cisplatin—peripheral nervous system neoplasm	3.75e-05	0.000202	CcSEcCtD
Lansoprazole—Erythema—Epirubicin—peripheral nervous system neoplasm	3.75e-05	0.000202	CcSEcCtD
Lansoprazole—Malnutrition—Epirubicin—peripheral nervous system neoplasm	3.75e-05	0.000202	CcSEcCtD
Lansoprazole—Diarrhoea—Etoposide—peripheral nervous system neoplasm	3.73e-05	0.000201	CcSEcCtD
Lansoprazole—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	3.72e-05	0.0002	CcSEcCtD
Lansoprazole—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	3.71e-05	0.0002	CcSEcCtD
Lansoprazole—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	3.7e-05	0.000199	CcSEcCtD
Lansoprazole—Flatulence—Epirubicin—peripheral nervous system neoplasm	3.69e-05	0.000199	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—NME1—peripheral nervous system neoplasm	3.69e-05	0.00127	CbGpPWpGaD
Lansoprazole—Tension—Epirubicin—peripheral nervous system neoplasm	3.68e-05	0.000198	CcSEcCtD
Lansoprazole—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	3.67e-05	0.000197	CcSEcCtD
Lansoprazole—Nervousness—Epirubicin—peripheral nervous system neoplasm	3.64e-05	0.000196	CcSEcCtD
Lansoprazole—Back pain—Epirubicin—peripheral nervous system neoplasm	3.62e-05	0.000195	CcSEcCtD
Lansoprazole—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	3.61e-05	0.000194	CcSEcCtD
Lansoprazole—Dizziness—Etoposide—peripheral nervous system neoplasm	3.61e-05	0.000194	CcSEcCtD
Lansoprazole—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	3.6e-05	0.000194	CcSEcCtD
Lansoprazole—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	3.6e-05	0.000194	CcSEcCtD
Lansoprazole—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	3.59e-05	0.000193	CcSEcCtD
Lansoprazole—CYP1A1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.58e-05	0.00123	CbGpPWpGaD
Lansoprazole—Chills—Doxorubicin—peripheral nervous system neoplasm	3.57e-05	0.000192	CcSEcCtD
Lansoprazole—ABCG2—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.57e-05	0.00123	CbGpPWpGaD
Lansoprazole—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	3.56e-05	0.000191	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—COX2—peripheral nervous system neoplasm	3.55e-05	0.00122	CbGpPWpGaD
Lansoprazole—Nausea—Cisplatin—peripheral nervous system neoplasm	3.54e-05	0.00019	CcSEcCtD
Lansoprazole—Vision blurred—Epirubicin—peripheral nervous system neoplasm	3.53e-05	0.00019	CcSEcCtD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	3.52e-05	0.00121	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	3.52e-05	0.00121	CbGpPWpGaD
Lansoprazole—Alopecia—Doxorubicin—peripheral nervous system neoplasm	3.52e-05	0.000189	CcSEcCtD
Lansoprazole—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	3.49e-05	0.000188	CcSEcCtD
Lansoprazole—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	3.48e-05	0.000187	CcSEcCtD
Lansoprazole—Vomiting—Etoposide—peripheral nervous system neoplasm	3.47e-05	0.000187	CcSEcCtD
Lansoprazole—Erythema—Doxorubicin—peripheral nervous system neoplasm	3.47e-05	0.000187	CcSEcCtD
Lansoprazole—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	3.47e-05	0.000187	CcSEcCtD
Lansoprazole—Anaemia—Epirubicin—peripheral nervous system neoplasm	3.46e-05	0.000186	CcSEcCtD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	3.46e-05	0.00119	CbGpPWpGaD
Lansoprazole—Agitation—Epirubicin—peripheral nervous system neoplasm	3.44e-05	0.000185	CcSEcCtD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	3.44e-05	0.00118	CbGpPWpGaD
Lansoprazole—Rash—Etoposide—peripheral nervous system neoplasm	3.44e-05	0.000185	CcSEcCtD
Lansoprazole—Dermatitis—Etoposide—peripheral nervous system neoplasm	3.44e-05	0.000185	CcSEcCtD
Lansoprazole—Headache—Etoposide—peripheral nervous system neoplasm	3.42e-05	0.000184	CcSEcCtD
Lansoprazole—Flatulence—Doxorubicin—peripheral nervous system neoplasm	3.42e-05	0.000184	CcSEcCtD
Lansoprazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—peripheral nervous system neoplasm	3.41e-05	0.00117	CbGpPWpGaD
Lansoprazole—Tension—Doxorubicin—peripheral nervous system neoplasm	3.4e-05	0.000183	CcSEcCtD
Lansoprazole—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	3.39e-05	0.000183	CcSEcCtD
Lansoprazole—Malaise—Epirubicin—peripheral nervous system neoplasm	3.38e-05	0.000182	CcSEcCtD
Lansoprazole—Nervousness—Doxorubicin—peripheral nervous system neoplasm	3.37e-05	0.000181	CcSEcCtD
Lansoprazole—Vertigo—Epirubicin—peripheral nervous system neoplasm	3.37e-05	0.000181	CcSEcCtD
Lansoprazole—Syncope—Epirubicin—peripheral nervous system neoplasm	3.36e-05	0.000181	CcSEcCtD
Lansoprazole—Leukopenia—Epirubicin—peripheral nervous system neoplasm	3.35e-05	0.000181	CcSEcCtD
Lansoprazole—Back pain—Doxorubicin—peripheral nervous system neoplasm	3.35e-05	0.00018	CcSEcCtD
Lansoprazole—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	3.33e-05	0.000179	CcSEcCtD
Lansoprazole—Palpitations—Epirubicin—peripheral nervous system neoplasm	3.31e-05	0.000178	CcSEcCtD
Lansoprazole—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	3.29e-05	0.000177	CcSEcCtD
Lansoprazole—CYP2C8—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.28e-05	0.00113	CbGpPWpGaD
Lansoprazole—Cough—Epirubicin—peripheral nervous system neoplasm	3.27e-05	0.000176	CcSEcCtD
Lansoprazole—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	3.27e-05	0.000176	CcSEcCtD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	3.26e-05	0.00112	CbGpPWpGaD
Lansoprazole—Convulsion—Epirubicin—peripheral nervous system neoplasm	3.25e-05	0.000175	CcSEcCtD
Lansoprazole—Nausea—Etoposide—peripheral nervous system neoplasm	3.24e-05	0.000174	CcSEcCtD
Lansoprazole—Hypertension—Epirubicin—peripheral nervous system neoplasm	3.23e-05	0.000174	CcSEcCtD
Lansoprazole—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	3.22e-05	0.000173	CcSEcCtD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	3.21e-05	0.00111	CbGpPWpGaD
Lansoprazole—Anaemia—Doxorubicin—peripheral nervous system neoplasm	3.2e-05	0.000172	CcSEcCtD
Lansoprazole—Myalgia—Epirubicin—peripheral nervous system neoplasm	3.19e-05	0.000172	CcSEcCtD
Lansoprazole—Chest pain—Epirubicin—peripheral nervous system neoplasm	3.19e-05	0.000172	CcSEcCtD
Lansoprazole—Arthralgia—Epirubicin—peripheral nervous system neoplasm	3.19e-05	0.000172	CcSEcCtD
Lansoprazole—Agitation—Doxorubicin—peripheral nervous system neoplasm	3.19e-05	0.000171	CcSEcCtD
Lansoprazole—Anxiety—Epirubicin—peripheral nervous system neoplasm	3.18e-05	0.000171	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	3.17e-05	0.00017	CcSEcCtD
Lansoprazole—Discomfort—Epirubicin—peripheral nervous system neoplasm	3.15e-05	0.00017	CcSEcCtD
Lansoprazole—Malaise—Doxorubicin—peripheral nervous system neoplasm	3.13e-05	0.000168	CcSEcCtD
Lansoprazole—Dry mouth—Epirubicin—peripheral nervous system neoplasm	3.12e-05	0.000168	CcSEcCtD
Lansoprazole—Vertigo—Doxorubicin—peripheral nervous system neoplasm	3.11e-05	0.000168	CcSEcCtD
Lansoprazole—Syncope—Doxorubicin—peripheral nervous system neoplasm	3.11e-05	0.000167	CcSEcCtD
Lansoprazole—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	3.1e-05	0.000167	CcSEcCtD
Lansoprazole—Confusional state—Epirubicin—peripheral nervous system neoplasm	3.08e-05	0.000166	CcSEcCtD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	3.07e-05	0.00106	CbGpPWpGaD
Lansoprazole—Palpitations—Doxorubicin—peripheral nervous system neoplasm	3.06e-05	0.000165	CcSEcCtD
Lansoprazole—Oedema—Epirubicin—peripheral nervous system neoplasm	3.06e-05	0.000165	CcSEcCtD
Lansoprazole—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	3.06e-05	0.000165	CcSEcCtD
Lansoprazole—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	3.05e-05	0.000164	CcSEcCtD
Lansoprazole—Infection—Epirubicin—peripheral nervous system neoplasm	3.04e-05	0.000164	CcSEcCtD
Lansoprazole—Cough—Doxorubicin—peripheral nervous system neoplasm	3.03e-05	0.000163	CcSEcCtD
Lansoprazole—Shock—Epirubicin—peripheral nervous system neoplasm	3.01e-05	0.000162	CcSEcCtD
Lansoprazole—Convulsion—Doxorubicin—peripheral nervous system neoplasm	3e-05	0.000162	CcSEcCtD
Lansoprazole—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	3e-05	0.000161	CcSEcCtD
Lansoprazole—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	2.99e-05	0.000161	CcSEcCtD
Lansoprazole—Hypertension—Doxorubicin—peripheral nervous system neoplasm	2.99e-05	0.000161	CcSEcCtD
Lansoprazole—Tachycardia—Epirubicin—peripheral nervous system neoplasm	2.98e-05	0.000161	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—CASP3—peripheral nervous system neoplasm	2.98e-05	0.00102	CbGpPWpGaD
Lansoprazole—Skin disorder—Epirubicin—peripheral nervous system neoplasm	2.97e-05	0.00016	CcSEcCtD
Lansoprazole—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	2.96e-05	0.000159	CcSEcCtD
Lansoprazole—Chest pain—Doxorubicin—peripheral nervous system neoplasm	2.95e-05	0.000159	CcSEcCtD
Lansoprazole—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	2.95e-05	0.000159	CcSEcCtD
Lansoprazole—Myalgia—Doxorubicin—peripheral nervous system neoplasm	2.95e-05	0.000159	CcSEcCtD
Lansoprazole—Anxiety—Doxorubicin—peripheral nervous system neoplasm	2.94e-05	0.000158	CcSEcCtD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	2.94e-05	0.00101	CbGpPWpGaD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	2.93e-05	0.000158	CcSEcCtD
Lansoprazole—CYP2C19—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.93e-05	0.00101	CbGpPWpGaD
Lansoprazole—Discomfort—Doxorubicin—peripheral nervous system neoplasm	2.92e-05	0.000157	CcSEcCtD
Lansoprazole—Anorexia—Epirubicin—peripheral nervous system neoplasm	2.91e-05	0.000157	CcSEcCtD
Lansoprazole—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	2.89e-05	0.000155	CcSEcCtD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	2.86e-05	0.000984	CbGpPWpGaD
Lansoprazole—Hypotension—Epirubicin—peripheral nervous system neoplasm	2.86e-05	0.000154	CcSEcCtD
Lansoprazole—ABCB1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.86e-05	0.000983	CbGpPWpGaD
Lansoprazole—Confusional state—Doxorubicin—peripheral nervous system neoplasm	2.85e-05	0.000154	CcSEcCtD
Lansoprazole—CYP1B1—Metabolism—GNS—peripheral nervous system neoplasm	2.84e-05	0.000976	CbGpPWpGaD
Lansoprazole—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	2.83e-05	0.000152	CcSEcCtD
Lansoprazole—Oedema—Doxorubicin—peripheral nervous system neoplasm	2.83e-05	0.000152	CcSEcCtD
Lansoprazole—Infection—Doxorubicin—peripheral nervous system neoplasm	2.81e-05	0.000151	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	2.79e-05	0.00015	CcSEcCtD
Lansoprazole—Shock—Doxorubicin—peripheral nervous system neoplasm	2.78e-05	0.00015	CcSEcCtD
Lansoprazole—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	2.77e-05	0.000149	CcSEcCtD
Lansoprazole—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	2.77e-05	0.000149	CcSEcCtD
Lansoprazole—Insomnia—Epirubicin—peripheral nervous system neoplasm	2.77e-05	0.000149	CcSEcCtD
Lansoprazole—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	2.76e-05	0.000149	CcSEcCtD
Lansoprazole—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	2.75e-05	0.000148	CcSEcCtD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	2.75e-05	0.000946	CbGpPWpGaD
Lansoprazole—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	2.75e-05	0.000148	CcSEcCtD
Lansoprazole—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	2.74e-05	0.000147	CcSEcCtD
Lansoprazole—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	2.73e-05	0.000147	CcSEcCtD
Lansoprazole—CYP1B1—Metabolism—NME1—peripheral nervous system neoplasm	2.72e-05	0.000936	CbGpPWpGaD
Lansoprazole—Somnolence—Epirubicin—peripheral nervous system neoplasm	2.72e-05	0.000146	CcSEcCtD
Lansoprazole—Anorexia—Doxorubicin—peripheral nervous system neoplasm	2.7e-05	0.000145	CcSEcCtD
Lansoprazole—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	2.69e-05	0.000145	CcSEcCtD
Lansoprazole—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.69e-05	0.000926	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	2.69e-05	0.000926	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.67e-05	0.000918	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—ENO2—peripheral nervous system neoplasm	2.67e-05	0.000918	CbGpPWpGaD
Lansoprazole—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	2.66e-05	0.000143	CcSEcCtD
Lansoprazole—Hypotension—Doxorubicin—peripheral nervous system neoplasm	2.64e-05	0.000142	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	2.64e-05	0.000142	CcSEcCtD
Lansoprazole—Fatigue—Epirubicin—peripheral nervous system neoplasm	2.64e-05	0.000142	CcSEcCtD
Lansoprazole—CYP1B1—Metabolism—COX2—peripheral nervous system neoplasm	2.62e-05	0.000901	CbGpPWpGaD
Lansoprazole—Pain—Epirubicin—peripheral nervous system neoplasm	2.61e-05	0.000141	CcSEcCtD
Lansoprazole—Constipation—Epirubicin—peripheral nervous system neoplasm	2.61e-05	0.000141	CcSEcCtD
Lansoprazole—ABCG2—Metabolism—GNS—peripheral nervous system neoplasm	2.58e-05	0.000888	CbGpPWpGaD
Lansoprazole—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	2.58e-05	0.000139	CcSEcCtD
Lansoprazole—Insomnia—Doxorubicin—peripheral nervous system neoplasm	2.56e-05	0.000138	CcSEcCtD
Lansoprazole—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	2.54e-05	0.000137	CcSEcCtD
Lansoprazole—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	2.52e-05	0.000136	CcSEcCtD
Lansoprazole—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	2.52e-05	0.000136	CcSEcCtD
Lansoprazole—Somnolence—Doxorubicin—peripheral nervous system neoplasm	2.52e-05	0.000135	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	2.5e-05	0.000135	CcSEcCtD
Lansoprazole—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	2.49e-05	0.000134	CcSEcCtD
Lansoprazole—ABCG2—Metabolism—NME1—peripheral nervous system neoplasm	2.47e-05	0.000851	CbGpPWpGaD
Lansoprazole—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	2.46e-05	0.000132	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	2.44e-05	0.000131	CcSEcCtD
Lansoprazole—Fatigue—Doxorubicin—peripheral nervous system neoplasm	2.44e-05	0.000131	CcSEcCtD
Lansoprazole—Urticaria—Epirubicin—peripheral nervous system neoplasm	2.43e-05	0.000131	CcSEcCtD
Lansoprazole—Constipation—Doxorubicin—peripheral nervous system neoplasm	2.42e-05	0.00013	CcSEcCtD
Lansoprazole—Pain—Doxorubicin—peripheral nervous system neoplasm	2.42e-05	0.00013	CcSEcCtD
Lansoprazole—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	2.42e-05	0.00013	CcSEcCtD
Lansoprazole—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	2.42e-05	0.00013	CcSEcCtD
Lansoprazole—CYP1A1—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.42e-05	0.000831	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—COX2—peripheral nervous system neoplasm	2.38e-05	0.000819	CbGpPWpGaD
Lansoprazole—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	2.33e-05	0.000125	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—ENO2—peripheral nervous system neoplasm	2.33e-05	0.000802	CbGpPWpGaD
Lansoprazole—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	2.31e-05	0.000125	CcSEcCtD
Lansoprazole—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.28e-05	0.000785	CbGpPWpGaD
Lansoprazole—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	2.25e-05	0.000121	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism—BCHE—peripheral nervous system neoplasm	2.25e-05	0.000775	CbGpPWpGaD
Lansoprazole—Urticaria—Doxorubicin—peripheral nervous system neoplasm	2.25e-05	0.000121	CcSEcCtD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	2.25e-05	0.000773	CbGpPWpGaD
Lansoprazole—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	2.24e-05	0.00012	CcSEcCtD
Lansoprazole—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	2.24e-05	0.00012	CcSEcCtD
Lansoprazole—CYP2C8—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.21e-05	0.000762	CbGpPWpGaD
Lansoprazole—Asthenia—Epirubicin—peripheral nervous system neoplasm	2.19e-05	0.000118	CcSEcCtD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	2.16e-05	0.000745	CbGpPWpGaD
Lansoprazole—Pruritus—Epirubicin—peripheral nervous system neoplasm	2.16e-05	0.000116	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.15e-05	0.00074	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	2.12e-05	0.000731	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—TH—peripheral nervous system neoplasm	2.12e-05	0.000729	CbGpPWpGaD
Lansoprazole—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	2.09e-05	0.000113	CcSEcCtD
Lansoprazole—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	2.08e-05	0.000112	CcSEcCtD
Lansoprazole—Asthenia—Doxorubicin—peripheral nervous system neoplasm	2.03e-05	0.000109	CcSEcCtD
Lansoprazole—Dizziness—Epirubicin—peripheral nervous system neoplasm	2.02e-05	0.000109	CcSEcCtD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	2.01e-05	0.000691	CbGpPWpGaD
Lansoprazole—Pruritus—Doxorubicin—peripheral nervous system neoplasm	2e-05	0.000108	CcSEcCtD
Lansoprazole—CYP2C19—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.98e-05	0.00068	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—BCHE—peripheral nervous system neoplasm	1.97e-05	0.000678	CbGpPWpGaD
Lansoprazole—Vomiting—Epirubicin—peripheral nervous system neoplasm	1.94e-05	0.000105	CcSEcCtD
Lansoprazole—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	1.94e-05	0.000104	CcSEcCtD
Lansoprazole—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.93e-05	0.000664	CbGpPWpGaD
Lansoprazole—Rash—Epirubicin—peripheral nervous system neoplasm	1.93e-05	0.000104	CcSEcCtD
Lansoprazole—Dermatitis—Epirubicin—peripheral nervous system neoplasm	1.93e-05	0.000104	CcSEcCtD
Lansoprazole—Headache—Epirubicin—peripheral nervous system neoplasm	1.92e-05	0.000103	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.88e-05	0.000646	CbGpPWpGaD
Lansoprazole—Dizziness—Doxorubicin—peripheral nervous system neoplasm	1.87e-05	0.000101	CcSEcCtD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	1.86e-05	0.000641	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—TH—peripheral nervous system neoplasm	1.85e-05	0.000637	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.84e-05	0.000633	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.82e-05	0.000626	CbGpPWpGaD
Lansoprazole—Nausea—Epirubicin—peripheral nervous system neoplasm	1.82e-05	9.78e-05	CcSEcCtD
Lansoprazole—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.8e-05	0.00062	CbGpPWpGaD
Lansoprazole—Vomiting—Doxorubicin—peripheral nervous system neoplasm	1.8e-05	9.68e-05	CcSEcCtD
Lansoprazole—Rash—Doxorubicin—peripheral nervous system neoplasm	1.78e-05	9.6e-05	CcSEcCtD
Lansoprazole—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	1.78e-05	9.59e-05	CcSEcCtD
Lansoprazole—Headache—Doxorubicin—peripheral nervous system neoplasm	1.77e-05	9.54e-05	CcSEcCtD
Lansoprazole—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.76e-05	0.000606	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GNS—peripheral nervous system neoplasm	1.75e-05	0.000601	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—GNAS—peripheral nervous system neoplasm	1.73e-05	0.000595	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—ENO2—peripheral nervous system neoplasm	1.72e-05	0.000591	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—ABCB1—peripheral nervous system neoplasm	1.7e-05	0.000584	CbGpPWpGaD
Lansoprazole—Nausea—Doxorubicin—peripheral nervous system neoplasm	1.68e-05	9.05e-05	CcSEcCtD
Lansoprazole—CYP1A1—Metabolism—NME1—peripheral nervous system neoplasm	1.67e-05	0.000576	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.64e-05	0.000565	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	1.62e-05	0.000557	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—COX2—peripheral nervous system neoplasm	1.61e-05	0.000555	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GNS—peripheral nervous system neoplasm	1.6e-05	0.000551	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—ENO2—peripheral nervous system neoplasm	1.56e-05	0.000538	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.54e-05	0.00053	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—NME1—peripheral nervous system neoplasm	1.53e-05	0.000528	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—GNAS—peripheral nervous system neoplasm	1.51e-05	0.00052	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.5e-05	0.000515	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—ABCB1—peripheral nervous system neoplasm	1.48e-05	0.00051	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—COX2—peripheral nervous system neoplasm	1.48e-05	0.000508	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	1.47e-05	0.000506	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.45e-05	0.000501	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—BCHE—peripheral nervous system neoplasm	1.45e-05	0.0005	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GNS—peripheral nervous system neoplasm	1.43e-05	0.000492	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	1.39e-05	0.00048	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.38e-05	0.000477	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—NME1—peripheral nervous system neoplasm	1.37e-05	0.000472	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—TH—peripheral nervous system neoplasm	1.36e-05	0.00047	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	1.34e-05	0.00046	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—BCHE—peripheral nervous system neoplasm	1.32e-05	0.000454	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—COX2—peripheral nervous system neoplasm	1.32e-05	0.000454	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	1.31e-05	0.000452	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	1.3e-05	0.000448	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	1.29e-05	0.000443	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.28e-05	0.00044	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	1.26e-05	0.000434	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.26e-05	0.000434	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	1.25e-05	0.00043	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—TH—peripheral nervous system neoplasm	1.24e-05	0.000427	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	1.21e-05	0.000417	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	1.2e-05	0.000414	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.19e-05	0.000409	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.17e-05	0.000403	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	1.15e-05	0.000395	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—GNAS—peripheral nervous system neoplasm	1.11e-05	0.000383	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	1.11e-05	0.000383	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—ABCB1—peripheral nervous system neoplasm	1.09e-05	0.000376	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	1.07e-05	0.000367	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ENO2—peripheral nervous system neoplasm	1.06e-05	0.000364	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	1.03e-05	0.000354	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—GNAS—peripheral nervous system neoplasm	1.01e-05	0.000349	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—ABCB1—peripheral nervous system neoplasm	9.95e-06	0.000342	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ENO2—peripheral nervous system neoplasm	9.7e-06	0.000334	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	9.42e-06	0.000324	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—BCHE—peripheral nervous system neoplasm	8.94e-06	0.000308	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ENO2—peripheral nervous system neoplasm	8.66e-06	0.000298	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	8.59e-06	0.000296	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.53e-06	0.000293	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	8.45e-06	0.000291	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—TH—peripheral nervous system neoplasm	8.4e-06	0.000289	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	8.24e-06	0.000284	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—BCHE—peripheral nervous system neoplasm	8.2e-06	0.000282	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	7.96e-06	0.000274	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	7.95e-06	0.000274	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	7.93e-06	0.000273	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	7.89e-06	0.000272	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.82e-06	0.000269	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—TH—peripheral nervous system neoplasm	7.71e-06	0.000265	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—BCHE—peripheral nervous system neoplasm	7.32e-06	0.000252	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	7.14e-06	0.000246	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.98e-06	0.00024	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—TH—peripheral nervous system neoplasm	6.88e-06	0.000237	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GNAS—peripheral nervous system neoplasm	6.86e-06	0.000236	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.81e-06	0.000234	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	6.75e-06	0.000232	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ABCB1—peripheral nervous system neoplasm	6.73e-06	0.000232	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	6.73e-06	0.000232	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	6.71e-06	0.000231	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	6.67e-06	0.00023	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.42e-06	0.000221	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.36e-06	0.000219	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	6.33e-06	0.000218	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GNAS—peripheral nervous system neoplasm	6.29e-06	0.000216	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	6.27e-06	0.000216	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ABCB1—peripheral nervous system neoplasm	6.17e-06	0.000212	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	5.7e-06	0.000196	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GNAS—peripheral nervous system neoplasm	5.61e-06	0.000193	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ABCB1—peripheral nervous system neoplasm	5.51e-06	0.00019	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	5.48e-06	0.000189	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.44e-06	0.000187	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	5.36e-06	0.000184	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	5.21e-06	0.000179	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	5.16e-06	0.000178	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	5.12e-06	0.000176	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	5.07e-06	0.000174	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	5.02e-06	0.000173	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—AKT1—peripheral nervous system neoplasm	4.67e-06	0.000161	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	4.4e-06	0.000151	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	4.37e-06	0.000151	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	4.29e-06	0.000148	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.2e-06	0.000144	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	4.14e-06	0.000142	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—AKT1—peripheral nervous system neoplasm	4.08e-06	0.00014	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	3.38e-06	0.000116	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	3.31e-06	0.000114	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—AKT1—peripheral nervous system neoplasm	3.01e-06	0.000103	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	2.74e-06	9.42e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—AKT1—peripheral nervous system neoplasm	1.85e-06	6.37e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—AKT1—peripheral nervous system neoplasm	1.7e-06	5.84e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—AKT1—peripheral nervous system neoplasm	1.52e-06	5.22e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	1.48e-06	5.09e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	1.39e-06	4.8e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	1.38e-06	4.76e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	1.18e-06	4.06e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	9.11e-07	3.14e-05	CbGpPWpGaD
